dc.contributor.author |
Roberts, Laura Christl
|
|
dc.contributor.author |
Abernethy, D.A. (Darrell)
|
|
dc.contributor.author |
Roberts, David Gordon
|
|
dc.contributor.author |
Ludynia, Katrin
|
|
dc.contributor.author |
O'Kennedy, Martha Magaretha
|
|
dc.contributor.author |
Abolnik, Celia
|
|
dc.date.accessioned |
2024-01-09T07:45:19Z |
|
dc.date.available |
2024-01-09T07:45:19Z |
|
dc.date.issued |
2024-01 |
|
dc.description |
DATA AVAILABILITY STATEMENT : The data that support the findings of this study are available from the corresponding author upon reasonable request. |
en_US |
dc.description.abstract |
BACKGROUND : High-pathogenicity avian influenza (HPAI) has become a conservation threat to wild birds. Therefore, suitable vaccine technology and practical application methods require investigation.
METHODS : Twenty-four African penguins (Spheniscus demersus) were vaccinated with either a conventional inactivated clade 2.3.4.4b H5N8 HPAI whole virus or a tobacco leaf-produced H5 haemagglutinin-based virus-like particle (VLP). Six birds received a second dose of the inactivated vaccine. Antibody responses were assessed and compared by employing haemagglutination inhibition tests.
RESULTS : A second dose of inactivated vaccine was required to induce antibody titres above the level required to suppress virus shedding, while a single dose of VLP vaccine produced these levels by day 14, and one bird still had antibodies on day 430.
LIMITATIONS : Bacterial contamination of the VLP vaccine limited the monitoring period and sample size in that treatment group, and it was not possible to perform a challenge study with field virus.
CONCLUSION : VLP vaccines offer a more practical option than inactivated whole viruses, especially in logistically challenging situations involving wild birds. |
en_US |
dc.description.department |
Centre for Veterinary Wildlife Studies |
en_US |
dc.description.department |
Production Animal Studies |
en_US |
dc.description.librarian |
hj2023 |
en_US |
dc.description.sdg |
SDG-03:Good heatlh and well-being |
en_US |
dc.description.sponsorship |
NRF-DSI SARChI and Health and Welfare Sector Education and Training Authority. |
en_US |
dc.description.uri |
https://wileyonlinelibrary.com/journal/vetr |
en_US |
dc.identifier.citation |
Roberts, L.C., Abernethy, D., Roberts, D.G., Ludynia, K., O'Kennedy, M.M. & Abolnik, C. Vaccination of African penguins (Spheniscus demersus) against high-pathogenicity avian influenza. Veterinary Record 2024, vol. 194, no. 2, art. e3616, pp. 1-5, https://doi.org/10.1002/vetr.3616. |
en_US |
dc.identifier.issn |
0042-4900 (print) |
|
dc.identifier.issn |
2042-7670 (online) |
|
dc.identifier.other |
10.1002/vetr.3616 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/93867 |
|
dc.language.iso |
en |
en_US |
dc.publisher |
Wiley |
en_US |
dc.rights |
© 2023 The Authors. Veterinary Record published by John Wiley & Sons Ltd on behalf of British Veterinary Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License. |
en_US |
dc.subject |
High-pathogenicity avian influenza (HPAI) |
en_US |
dc.subject |
African penguins (Spheniscus demersus) |
en_US |
dc.subject |
Wild birds |
en_US |
dc.subject |
Virus-like particle (VLP) |
en_US |
dc.subject |
VLP vaccine |
en_US |
dc.subject |
SDG-03: Good health and well-being |
en_US |
dc.title |
Vaccination of African penguins (Spheniscus demersus) against high-pathogenicity avian influenza |
en_US |
dc.type |
Article |
en_US |